145 related articles for article (PubMed ID: 9209657)
1. Characteristics of human EBV-specific cytotoxic T lymphocytes utilized for adoptive immunotherapy of EBV-induced lymphoproliferations in xenografted SCID mice.
Lacerda JF; O'Reilly RJ
Ann Oncol; 1997; 8 Suppl 2():137-40. PubMed ID: 9209657
[TBL] [Abstract][Full Text] [Related]
2. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice.
Lacerda JF; Ladanyi M; Louie DC; Fernandez JM; Papadopoulos EB; O'Reilly RJ
J Exp Med; 1996 Mar; 183(3):1215-28. PubMed ID: 8642263
[TBL] [Abstract][Full Text] [Related]
3. Endogenous CD8+ T cell expansion during regression of monoclonal EBV-associated posttransplant lymphoproliferative disorder.
Khatri VP; Baiocchi RA; Peng R; Oberkircher AR; Dolce JM; Ward PM; Herzig GP; Caligiuri MA
J Immunol; 1999 Jul; 163(1):500-6. PubMed ID: 10384154
[TBL] [Abstract][Full Text] [Related]
4. Generation of EBV-specific CTLs suitable for adoptive immunotherapy of EBV-associated lymphoproliferative disease following allogeneic transplantation.
Hoffmann T; Russell C; Vindelov L
APMIS; 2002 Feb; 110(2):148-57. PubMed ID: 12064870
[TBL] [Abstract][Full Text] [Related]
5. Regulation of human cell engraftment and development of EBV-related lymphoproliferative disorders in Hu-PBL-scid mice.
Wagar EJ; Cromwell MA; Shultz LD; Woda BA; Sullivan JL; Hesselton RM; Greiner DL
J Immunol; 2000 Jul; 165(1):518-27. PubMed ID: 10861091
[TBL] [Abstract][Full Text] [Related]
6. Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation.
Nolte A; Buhmann R; Straka C; Emmerich B; Hallek M
Bone Marrow Transplant; 1998 May; 21(9):909-16. PubMed ID: 9613783
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus, B cell lymphoproliferative disease, and SCID mice: modeling T cell immunotherapy in vivo.
Johannessen I; Bieleski L; Urquhart G; Watson SL; Wingate P; Haque T; Crawford DH
J Med Virol; 2011 Sep; 83(9):1585-96. PubMed ID: 21739450
[TBL] [Abstract][Full Text] [Related]
8. Ex vivo generation of cytotoxic T lymphocytes specific for one or two distinct viruses for the prophylaxis of patients receiving an allogeneic bone marrow transplant.
Regn S; Raffegerst S; Chen X; Schendel D; Kolb HJ; Roskrow M
Bone Marrow Transplant; 2001 Jan; 27(1):53-64. PubMed ID: 11244438
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.
Gustafsson A; Levitsky V; Zou JZ; Frisan T; Dalianis T; Ljungman P; Ringden O; Winiarski J; Ernberg I; Masucci MG
Blood; 2000 Feb; 95(3):807-14. PubMed ID: 10648390
[TBL] [Abstract][Full Text] [Related]
10. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients.
Savoldo B; Goss J; Liu Z; Huls MH; Doster S; Gee AP; Brenner MK; Heslop HE; Rooney CM
Transplantation; 2001 Sep; 72(6):1078-86. PubMed ID: 11579304
[TBL] [Abstract][Full Text] [Related]
11. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cells improve the generation of Epstein-Barr virus-specific cytotoxic T lymphocytes for the treatment of posttransplantation lymphoma.
Wheatley GH; McKinnon KP; Iacobucci M; Mahon S; Gelber C; Lyerly HK
Surgery; 1998 Aug; 124(2):171-6. PubMed ID: 9706135
[TBL] [Abstract][Full Text] [Related]
13. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection.
Savoldo B; Huls MH; Liu Z; Okamura T; Volk HD; Reinke P; Sabat R; Babel N; Jones JF; Webster-Cyriaque J; Gee AP; Brenner MK; Heslop HE; Rooney CM
Blood; 2002 Dec; 100(12):4059-66. PubMed ID: 12393655
[TBL] [Abstract][Full Text] [Related]
14. Multiple HLA class I-dependent cytotoxicities constitute the "non-HLA-restricted" response in infectious mononucleosis.
Strang G; Rickinson AB
Eur J Immunol; 1987 Jul; 17(7):1007-13. PubMed ID: 2440688
[TBL] [Abstract][Full Text] [Related]
15. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo priming of naïve T cells into EBV-specific Th1/Tc1 effector cells by mature autologous DC loaded with apoptotic/necrotic LCL.
Popescu I; Macedo C; Zeevi A; Nellis J; Patterson KR; Logar A; Rowe D; Reyes J; Rao AS; Storkus WJ; Fung JJ; Metes D
Am J Transplant; 2003 Nov; 3(11):1369-77. PubMed ID: 14525597
[TBL] [Abstract][Full Text] [Related]
17. Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors.
Rossig C; Bär A; Pscherer S; Altvater B; Pule M; Rooney CM; Brenner MK; Jürgens H; Vormoor J
J Immunother; 2006; 29(1):21-31. PubMed ID: 16365597
[TBL] [Abstract][Full Text] [Related]
18. CD8+ T cell subsets of cytotoxic T lymphocytes induced by Epstein-Barr virus infection in infectious mononucleosis.
Ebihara T; Sakai N; Koyama S
Tohoku J Exp Med; 1990 Nov; 162(3):213-24. PubMed ID: 1965352
[TBL] [Abstract][Full Text] [Related]
19. Immune-cell treatment of Epstein--Barr-virus-associated lymphoproliferative disorders.
Swinnen LJ
Best Pract Res Clin Haematol; 2006; 19(4):839-47. PubMed ID: 16997187
[TBL] [Abstract][Full Text] [Related]
20. Stimulation with allogeneic Epstein-Barr virus-transformed lymphoblastoid cell lines generates HLA class I-specific CTLs with different target cell avidity.
Torsteinsdottir S; Cuomo L; Klein E; Masucci MG
Cell Immunol; 1991 Oct; 137(2):501-13. PubMed ID: 1654213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]